- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Off-label Medication Use of Asenapine Sublingual Tablets for Agitated Delirium in Cancer Patients at the End of Life
-
- Nakano Hiroki
- Department of Pharmacy, National Hospital Organization Osaka Medical Center Department of Pharmacy, National Hospital Organization Himeji Medical Center
-
- Akashi Naoko
- Department of Pharmacy, National Hospital Organization Himeji Medical Center
-
- Wada Tomomi
- Department of Palliative Care Medicine, Osaka General Hospital of West Japan Railway Company
-
- Ide Kyoko
- Department of Nursing, National Hospital Organization Osaka Medical Center
-
- Inoue Atsuyuki
- Department of Pharmacy, National Hospital Organization Osaka Medical Center
-
- Miyabe Takashi
- Department of Pharmacy, National Hospital Organization Osaka Medical Center
-
- Yamauchi Kazutaka
- Department of Pharmacy, National Hospital Organization Osaka Medical Center
Bibliographic Information
- Other Title
-
- 終末期がん患者のせん妄に対するアセナピン舌下錠の使用調査
Search this article
Description
<p>Delirium occurs in 30-40% of patients with terminal cancer, and 90% of patients are delirious immediately before death. Symptoms such as agitation and hallucination are often refractory to the standard pharmacological therapy. Also, the medication options for delirium in terminally ill patients are often limited due to a difficulty in swallowing or a lack of intravenous access. We herein report a case series of six patients with terminal cancer whose derilium symptoms were treated by asenapine sublingual tablets during the intervention period by the palliative care team. Asenapine was selected when other antipsychotics were ineffective or unavailable for agitation caused by delirium. All patients suffered dyspnea or choking sensations due to dysphagia or respiratory dysfunction. Sedative effect was observed among all patients without apparent adverse events. Sublingual asenapine could be an option for the management of restlessness due to terminal delirium when both oral and intravenous drug administration routes are not available.</p>
Journal
-
- Palliative Care Research
-
Palliative Care Research 16 (3), 261-265, 2021
Japanese Society for Palliative Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390007923747683456
-
- NII Article ID
- 130008088867
-
- ISSN
- 18805302
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed
